NewsBenzinga据报道,艾尔建美学 HALO 中期结果显示:在接受 HA 注射后,25 名使用 GLP-1 药物的成年人中有 95.7% 对“自己看起来仍像自己”感到满意或非常满意,FACE-Q 评分提升 39.6 分 据报道,艾尔建美学 HALO 中期结果显示:在接受 HA 注射后,25 名使用 GLP-1 药物的成年人中有 95.7% 对“自己看起来仍像自己”感到满意或非常满意,FACE-Q 评分提升 39.6 分 Benzinga 2026.11.09 08:00 (GMT+0) Open on Benzinga Other news Global-E Online Stock Is Falling Wednesday: What's Going On? Grifols Presents New Real-World Evidence Data From AMBAR Program, Contributing To Ongoing Research Evaluating Use Of TPE With Albumin Replacement In Patients With Alzheimer’s Disease HC Wainwright & Co. Maintains Buy on LifeMD, Lowers Price Target to $6 Stifel Maintains Buy on Ecolab, Raises Price Target to $356 Stifel Upgrades Tandem Diabetes Care to Buy, Raises Price Target to $26 Immuneering Presents Preclinical Data Demonstrating Potential Of Atebimetinib; Phase 2 Results Include Long Survival And Outstanding Tolerability Profile In First-Line Pancreatic Cancer Patients
Grifols Presents New Real-World Evidence Data From AMBAR Program, Contributing To Ongoing Research Evaluating Use Of TPE With Albumin Replacement In Patients With Alzheimer’s Disease
Immuneering Presents Preclinical Data Demonstrating Potential Of Atebimetinib; Phase 2 Results Include Long Survival And Outstanding Tolerability Profile In First-Line Pancreatic Cancer Patients